Century Therapeutics, Inc. (NASDAQ:IPSC) Short Interest Update

Century Therapeutics, Inc. (NASDAQ:IPSC) was the recipient of a significant decrease in short interest during the month of December. As of December 15th, there was short interest totaling 246,333 shares, a decrease of 59.5% from the November 30th total of 608,275 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 826,473 shares, the short-interest ratio is presently 0.3 days. Based on an average trading volume of 826,473 shares, the short-interest ratio is presently 0.3 days. Approximately 0.3% of the company’s shares are sold short.

Insider Activity at Century Therapeutics

In other Century Therapeutics news, CEO Brent Pfeiffenberger purchased 52,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $0.58 per share, with a total value of $30,160.00. Following the completion of the purchase, the chief executive officer directly owned 3,322,990 shares of the company’s stock, valued at $1,927,334.20. The trade was a 1.59% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 65,987 shares of company stock worth $29,798 over the last ninety days. Corporate insiders own 4.37% of the company’s stock.

Institutional Investors Weigh In On Century Therapeutics

Several large investors have recently bought and sold shares of the business. Prudential Financial Inc. bought a new position in Century Therapeutics during the 2nd quarter valued at about $25,000. Qube Research & Technologies Ltd purchased a new position in shares of Century Therapeutics during the second quarter valued at approximately $38,000. Y Intercept Hong Kong Ltd bought a new position in Century Therapeutics during the second quarter valued at approximately $50,000. Raymond James Financial Inc. purchased a new stake in Century Therapeutics in the second quarter worth approximately $51,000. Finally, AQR Capital Management LLC boosted its holdings in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company’s stock worth $53,000 after purchasing an additional 86,875 shares during the last quarter. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Stock Up 4.3%

Shares of NASDAQ IPSC traded up $0.05 during midday trading on Friday, hitting $1.09. The stock had a trading volume of 1,434,844 shares, compared to its average volume of 1,358,252. The business’s 50 day moving average is $0.61 and its 200-day moving average is $0.57. Century Therapeutics has a 52 week low of $0.34 and a 52 week high of $1.19. The company has a market cap of $94.83 million, a P/E ratio of -3.39 and a beta of 1.80.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. As a group, analysts expect that Century Therapeutics will post -1.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Leerink Partnrs cut shares of Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Century Therapeutics in a report on Wednesday, October 8th. Leerink Partners reaffirmed a “market perform” rating and set a $2.00 target price (down previously from $7.00) on shares of Century Therapeutics in a research note on Monday, November 17th. Finally, Wall Street Zen cut Century Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 20th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.40.

About Century Therapeutics

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.